Lisata Therapeutics, Inc. (LON:0HS8)

London flag London · Delayed Price · Currency is GBP · Price in USD
4.550
-0.010 (-0.22%)
At close: Feb 11, 2026
Market Cap29.35M +62.2%
Revenue (ttm)796.02K
Net Income-13.57M
EPS-1.58
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume201
Average Volume4,279
Open4.520
Previous Close4.560
Day's Range4.520 - 4.550
52-Week Range1.880 - 4.842
Beta1.28
RSI73.06
Earnings DateFeb 27, 2026

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is hea... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 26
Stock Exchange London Stock Exchange
Ticker Symbol 0HS8
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements